Attractive M&A options? Analysts break down what's hot right now
With the number of biopharma acquisitions in 2022 so far falling below recent years, the investment bank SVB Securities on Sunday published a new report on M&A and where there may be some action in the near term.
As far as the acquirers, the report notes that large biopharma companies’ execs have a “broad appetite for M&A and BD,” and companies like Pfizer and Johnson & Johnson are both carrying cash balances of about $33 billion each as of June 30, while other companies like Novartis with $20 billion, and Bristol Myers Squibb with $13 billion, can take the lead.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.